Syngene International
Bengaluru, India
Compare Biologics CDMOs in Asia
Compare Biologics CDMOs in India
Compare Cell Therapy CDMOs in Asia
Compare Cell Therapy CDMOs in India
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
80.3
Signal Score
✓ FDA Inspections (3)
○ Clinical Trials
○ SEC Filings
✓ Press (12)
○ EMA GMP
○ MHRA GMP
✓ HC GMP (16)
Quick Facts: Syngene International
- Signal Score
- 80.3/100 (as of 2026-10-29)
- Quality Compliance
- 100.0/100 — Bonus: 3 consecutive NAI inspections
- Headquarters
- Bengaluru, India
- Modalities
- Biologics, Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed — 1 partnership signal in press (announcements, not verified)
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Syngene International
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
Bonus: 3 consecutive NAI inspections
Sources: FDA Data Dashboard
Bonus: 3 consecutive NAI inspections
FDA Inspections3 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-02-20)
Most Recent HC OutcomeCompliant · 2025-02-10
HC Attribution16 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Bonus: 3 consecutive NAI inspections
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 1 partnership announcement found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesBiologics, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
Financial Stability
68.0
Parent company: Biocon
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Biocon
Financial assessment: 68.0/100
Capacity
58.0
1 manufacturing site: Bangalore, IN
Modalities: Biologics, Cell Therapy
Capacity assessment: 58.0/100
Sites: Bangalore, IN
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals12 articles (not scored)
1 manufacturing site: Bangalore, IN
Modalities: Biologics, Cell Therapy
Capacity assessment: 58.0/100
Syngene International FDA Inspection History
2025-02
2023-05
2022-10
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2025-02-20 |
Syngene International Ltd.
Bengaluru
Facility-linked
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2023-05-26 |
Syngene International Limited
Dakshina Kannada, Mangalore
Company-level
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2022-10-28 |
Syngene International Limited
Bengalore
Company-level
|
Bioresearch Monitoring | Not posted | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Japan-accredited overseas site (PMDA)
general (non-sterile) · 1 site
- Bengaluru, India · Syngene International Limited — general (non-sterile) · valid to May 18, 2027 renewal due
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Hiring Activity 4 open roles Beta
From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
4
open roles
3
in manufacturing, quality, PD/MSAT, engineering or regulatory (75%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 60 taken down.
By function
By site
Baltimore
· 1 PD/MSAT · 2 eng. · 1 other 4
· 1 PD/MSAT · 2 eng. · 1 other 4
Modality words in job titles
Biologics (cell culture, USP/DSP)1
Notable roles
Director Engineering and Maintenance
Senior operations / quality role · Baltimore
Latest postings
Senior Process Engineer
Process development & MSAT · Baltimore
Manager Facilities
Engineering & facilities · Baltimore
Director Engineering and Maintenance
Engineering & facilities · Baltimore
Director Business Development Biologics, East Coast U.S.
Commercial, BD & client projects · Baltimore
Coverage: read from the parent company's careers board and kept only postings at this business's sites (Baltimore biologics manufacturing site only. The Bangalore campus mixes research services and manufacturing, so it is left out and this count is low). Roles outside those sites are left out, and some of this unit's roles may be missed.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
careers.syngeneintl.com
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Company Signals 12 articles
Company announcements, not verified evidence. They do not change any score.
Syngene International (NSE:SYNGENE) Q2 FY27 Results and Business Update - Kalkine India
Syngene International (NSE:SYNGENE) Q2 FY27 Results and Business Update Kalkine India
Syngene International posts Rs 32.2-crore profit in Q2, rebounds from Q1 loss - ABP Live English
Syngene International posts Rs 32.2-crore profit in Q2, rebounds from Q1 loss ABP Live English
Syngene International: Q2 FY27 Revenue Up 13% Sequentially, EBITDA Margin Improves - InvestyWise
Syngene International: Q2 FY27 Revenue Up 13% Sequentially, EBITDA Margin Improves InvestyWise
Syngene International Reports Modest 3% FY26 Revenue Growth Amid Biologics Headwinds - IndiaMedToday
Syngene International Reports Modest 3% FY26 Revenue Growth Amid Biologics Headwinds IndiaMedToday
Syngene International Q4 net down 19 pc at Rs 147.9 cr - Devdiscourse
Syngene International Q4 net down 19 pc at Rs 147.9 cr Devdiscourse
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for - AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for - AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for - AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 - AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 - AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 AD HOC NEWS
Syngene International Stock (ISIN: INE398A01010) Faces Pressure Amid Biopharma Contract Slowdown - ad-hoc-news.de
Syngene International Stock (ISIN: INE398A01010) Faces Pressure Amid Biopharma Contract Slowdown AD HOC NEWS
VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure - BioSpace
VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure BioSpace
Frequently Asked Questions About Syngene International
How many FDA inspections does Syngene International have on record?
CDMO Signal tracks 3 FDA inspections for Syngene International, sourced from the FDA inspection database. See the full inspection history above.
Has Syngene International received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Syngene International.
What is Syngene International's CDMO Signal Score?
Syngene International has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating Syngene International for a manufacturing program?
Use the free AI matchmaker to compare Syngene International against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
Signal Score: 81.9
mRNA, Biologics, Cell Therapy
Eurofins CDMO
Planegg, DE · San Diego, CA
Signal Score: 81.6
Biologics, Cell Therapy
ProBio
Pennington, NJ · Nanjing, CN
Signal Score: 64.0
mRNA, Biologics, CAR-T, Cell Therapy
Singota Solutions
Bloomington, IN
Signal Score: 59.0
Cell Therapy, Biologics
Biocon Biologics
Bengaluru, India
Signal Score: 75.7
Cell Therapy
Compare Syngene International with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.